(R)-(+)-8-Hydroxy-DPAT hydrobromide

Discontinued Product

1080 has been discontinued.

View all 5-HT<sub>1A</sub> Receptors products.
说明: Selective 5-HT1A agonist; enantiomer of 8-Hydroxy-DPAT hydrobromide (Cat. No. 0529)
化学名: (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide
纯度: ≥98% (HPLC)
说明书
引用文献 (4)
评论 (1)
文献 (3)

生物活性 for (R)-(+)-8-Hydroxy-DPAT hydrobromide

(R)-(+)-8-Hydroxy-DPAT hydrobromide is a full 5-HT1A serotonin receptor agonist. Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. More active enantiomer of 8-Hydroxy-DPAT hydrobromide.

Racemate and 7-Hydroxy Isomer also available.

技术数据 for (R)-(+)-8-Hydroxy-DPAT hydrobromide

分子量 328.29
公式 C16H25NO.HBr
储存 Desiccate at +4°C
纯度 ≥98% (HPLC)
CAS Number 78095-19-9
PubChem ID 11957570
InChI Key BATPBOZTBNNDLN-PFEQFJNWSA-N
Smiles Br.CCCN(CCC)[C@@H]1CCC2=CC=CC(O)=C2C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for (R)-(+)-8-Hydroxy-DPAT hydrobromide

分析证书/产品说明书
选择另一批次:

按标靶查看相关产品

按产品操作查看相关产品

查看全部 5-HT1A Receptor Agonists

关键词: (R)-(+)-8-Hydroxy-DPAT hydrobromide, (R)-(+)-8-Hydroxy-DPAT hydrobromide supplier, Selective, 5-HT1A, agonists, active, enantiomer, Serotonin, Receptors, 1080, Tocris Bioscience

4 篇 (R)-(+)-8-Hydroxy-DPAT hydrobromide 的引用文献

引用文献是使用了 Tocris 产品的出版物。 (R)-(+)-8-Hydroxy-DPAT hydrobromide 的部分引用包括:

Wierońska et al (2015) The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies. Oncoscience 232 259 PMID: 25012236

Cassilly et al (2016) SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. Psychopharmacology (Berl) 11 e0154932 PMID: 27183222

Sadiq et al (2019) 5-HT1A Receptor Function Makes Wound Healing a Happier Process. Front Pharmacol 9 1406 PMID: 30618734

Rossi et al (2008) Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by cital. and escital. Eur J Pharmacol 583 103 PMID: 18289523


(R)-(+)-8-Hydroxy-DPAT hydrobromide 的评论

平均评分: 5 (Based on 1 Review.)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used (R)-(+)-8-Hydroxy-DPAT hydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


The 5,760 bioactive compound library is a collated compound set of approved drugs and biologically active compound.
By Anonymous on 02/01/2020
分析类型: In Vitro
种属: Other

Biologically active compounds that have been documented to interact with awide range of targets including SB-224289 (Cat. # 1221), MG-624 (Cat.# 1356), GVIA (Cat. No. 1085), DPAT hydrobromide (Cat. No. 1080) and valinomycin (VA; Cat. # 3373) were ordered from Tocris Bioscience

PMID: 27183222
review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.